雷替曲塞联合伊立替康或奥沙利铂在结直肠癌一线治疗失败后的临床应用对比研究. (Chinese)

Objective To comparatively analyze the clinical efficacy and safety of raltitrexed combined with irinotecan or oxaliplatin in patients with colorectal cancer after first-line treatment failure. Methods A total of 56 patients with colorectal cancer who had failed first-line treatment in our hospital between January 2018 and January 2020 were selected. They were randomly divided into group A and group B by random number table method, with 28 cases in each group. Patients in group A were treated with raltitrexed combined with irinotecan, and patients in group B were treated with raltitrexed combined with oxaliplatin. The disease control rate (DCR), response rate (RR), adverse reactions, progression-free survival (PFS) and overall survival (OS) were compared between the two groups. Results The RRs and DCRs of group A and B were 17.86% and 21.43%,57.14% and 64.29%, there being no statistically significant difference between the two groups (P>0.05). The rate of diarrhea in group A (32.14%) was higher than that in group B (7.14%), and the difference was statistically significant (P<0.05). Both groups were followed up for 4～21 months. The median PFS and median OS of group A were 8 months and 15 months, which of group B were 8 months and 15 months, there being no statistically significant difference between the two groups (P>0.05). Conclusion Raltitrexed combined with irinotecan or oxaliplatin is effective in the treatment of colorectal cancer patients with first-line treatment failure. Both can delay disease progression and prolong the survival time of the patients, with equivalent effects and tolerable adverse reactions. However, it is necessary to pay close attention to diarrhea in the patients treated with raltitrexed combined with irinotecan. [ABSTRACT FROM AUTHOR]

目的 比较分析雷替曲塞联合伊立替康或奥沙利铂对一线治疗失败结直肠癌患者的临床疗效和安全性。方法 选取我院2018年1月至2020年1月收治的一线治疗失败结直肠癌患者56例，采用随机数字表法将患者随机分为A组和B组，每组28例。A组患者接受雷替曲塞联合伊立替康治疗，B组患者接受雷替曲塞联合奥沙利铂治疗，比较两组患者的疾病控制率（DCR）、有效率（RR）、治疗不良反应、无进展生存期（PFS）和总生存期（OS）等。结果 A组和B组患者治疗RR分别为17.86%、21.43%,组间差异无统计学意义（P＞0.05）;A组和B组患者治疗DCR分别为57.14%、64.29%,组间差异无统计学意义（P＞0.05）;A组患者腹泻率高于B组患者（32.14%vs. 7.14%,P＜0.05）,差异有统计学意义；两组患者随访时间4～21个月，A组患者中位PFS为8个月，中位OS为15个月；B组患者中位PFS为8个月，中位OS为15个月。两组患者PFS和OS差异均无统计学意义（P＞0.05）。结论 雷替曲塞联合伊立替康或奥沙利铂在一线治疗失败的结直肠癌患者中的临床疗效明确，可延缓患者疾病进展，延长患者生存时间，且两者效果相当，不良反应均可耐受，使用雷替曲塞联合伊立替康治疗时，需密切关注患者腹泻情况. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)